vs
Dave Inc.（DAVE）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是Dave Inc.的1.3倍（$207.3M vs $163.7M），Dave Inc.净利率更高（40.3% vs -62.0%，领先102.3%），Dave Inc.同比增速更快（62.4% vs 25.9%），Dave Inc.自由现金流更多（$289.7M vs $-100.8M），过去两年Dave Inc.的营收复合增速更高（49.1% vs 38.0%）
Dave & Buster's是总部位于美国达拉斯的餐饮娱乐连锁品牌，旗下门店均配套全服务餐厅、酒吧，以及名为“百万美元中途岛”的电子游戏厅。截至2024年2月，品牌在美国拥有158家门店，波多黎各和加拿大各设有2家门店。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
DAVE vs RARE — 直观对比
营收规模更大
RARE
是对方的1.3倍
$163.7M
营收增速更快
DAVE
高出36.5%
25.9%
净利率更高
DAVE
高出102.3%
-62.0%
自由现金流更多
DAVE
多$390.5M
$-100.8M
两年增速更快
DAVE
近两年复合增速
38.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $163.7M | $207.3M |
| 净利润 | $65.9M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 39.2% | -54.7% |
| 净利率 | 40.3% | -62.0% |
| 营收同比 | 62.4% | 25.9% |
| 净利润同比 | 292.4% | 3.5% |
| 每股收益（稀释后） | $4.60 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DAVERARE
| Q4 25 | $163.7M | $207.3M | ||
| Q3 25 | $150.7M | $159.9M | ||
| Q2 25 | $131.8M | $166.5M | ||
| Q1 25 | $108.0M | $139.3M | ||
| Q4 24 | $100.8M | $164.6M | ||
| Q3 24 | $92.5M | $139.5M | ||
| Q2 24 | $80.1M | $147.0M | ||
| Q1 24 | $73.6M | $108.8M |
净利润DAVERARE
| Q4 25 | $65.9M | $-128.6M | ||
| Q3 25 | $92.1M | $-180.4M | ||
| Q2 25 | $9.0M | $-115.0M | ||
| Q1 25 | $28.8M | $-151.1M | ||
| Q4 24 | $16.8M | $-133.2M | ||
| Q3 24 | $466.0K | $-133.5M | ||
| Q2 24 | $6.4M | $-131.6M | ||
| Q1 24 | $34.2M | $-170.7M |
营业利润率DAVERARE
| Q4 25 | 39.2% | -54.7% | ||
| Q3 25 | 38.8% | -106.9% | ||
| Q2 25 | 8.7% | -64.8% | ||
| Q1 25 | 31.4% | -102.6% | ||
| Q4 24 | 17.3% | -74.3% | ||
| Q3 24 | 0.9% | -94.6% | ||
| Q2 24 | 5.7% | -79.1% | ||
| Q1 24 | 50.9% | -151.9% |
净利率DAVERARE
| Q4 25 | 40.3% | -62.0% | ||
| Q3 25 | 61.1% | -112.8% | ||
| Q2 25 | 6.9% | -69.0% | ||
| Q1 25 | 26.7% | -108.5% | ||
| Q4 24 | 16.7% | -80.9% | ||
| Q3 24 | 0.5% | -95.7% | ||
| Q2 24 | 7.9% | -89.5% | ||
| Q1 24 | 46.5% | -156.8% |
每股收益（稀释后）DAVERARE
| Q4 25 | $4.60 | $-1.28 | ||
| Q3 25 | $6.34 | $-1.81 | ||
| Q2 25 | $0.62 | $-1.17 | ||
| Q1 25 | $1.97 | $-1.57 | ||
| Q4 24 | $1.09 | $-1.34 | ||
| Q3 24 | $0.03 | $-1.40 | ||
| Q2 24 | $0.47 | $-1.52 | ||
| Q1 24 | $2.60 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $80.5M | $421.0M |
| 总债务越低越好 | $0 | — |
| 股东权益账面价值 | $352.7M | $-80.0M |
| 总资产 | $487.4M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资DAVERARE
| Q4 25 | $80.5M | $421.0M | ||
| Q3 25 | $49.9M | $202.5M | ||
| Q2 25 | $61.8M | $176.3M | ||
| Q1 25 | $47.1M | $127.1M | ||
| Q4 24 | $49.8M | $174.0M | ||
| Q3 24 | $35.2M | $150.6M | ||
| Q2 24 | $48.7M | $480.7M | ||
| Q1 24 | $56.6M | $112.3M |
总债务DAVERARE
| Q4 25 | $0 | — | ||
| Q3 25 | $75.0M | — | ||
| Q2 25 | $75.0M | — | ||
| Q1 25 | $75.0M | — | ||
| Q4 24 | $75.0M | — | ||
| Q3 24 | $75.0M | — | ||
| Q2 24 | $75.0M | — | ||
| Q1 24 | $75.0M | — |
股东权益DAVERARE
| Q4 25 | $352.7M | $-80.0M | ||
| Q3 25 | $291.3M | $9.2M | ||
| Q2 25 | $217.1M | $151.3M | ||
| Q1 25 | $199.5M | $144.2M | ||
| Q4 24 | $183.1M | $255.0M | ||
| Q3 24 | $155.8M | $346.8M | ||
| Q2 24 | $141.8M | $432.4M | ||
| Q1 24 | $127.3M | $140.3M |
总资产DAVERARE
| Q4 25 | $487.4M | $1.5B | ||
| Q3 25 | $433.3M | $1.2B | ||
| Q2 25 | $363.6M | $1.3B | ||
| Q1 25 | $315.7M | $1.3B | ||
| Q4 24 | $299.3M | $1.5B | ||
| Q3 24 | $272.2M | $1.5B | ||
| Q2 24 | $247.2M | $1.6B | ||
| Q1 24 | $235.6M | $1.3B |
负债/权益比DAVERARE
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.26× | — | ||
| Q2 25 | 0.35× | — | ||
| Q1 25 | 0.38× | — | ||
| Q4 24 | 0.41× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.53× | — | ||
| Q1 24 | 0.59× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $290.0M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $289.7M | $-100.8M |
| 自由现金流率自由现金流/营收 | 177.0% | -48.6% |
| 资本支出强度资本支出/营收 | 0.2% | 0.5% |
| 现金转化率经营现金流/净利润 | 4.40× | — |
| 过去12个月自由现金流最近4个季度 | $486.2M | $-472.0M |
8季度趋势，按日历期对齐
经营现金流DAVERARE
| Q4 25 | $290.0M | $-99.8M | ||
| Q3 25 | $83.2M | $-91.4M | ||
| Q2 25 | $68.2M | $-108.3M | ||
| Q1 25 | $45.2M | $-166.5M | ||
| Q4 24 | $125.1M | $-79.3M | ||
| Q3 24 | $37.0M | $-67.0M | ||
| Q2 24 | $28.0M | $-77.0M | ||
| Q1 24 | $18.3M | $-190.7M |
自由现金流DAVERARE
| Q4 25 | $289.7M | $-100.8M | ||
| Q3 25 | $83.2M | $-92.7M | ||
| Q2 25 | $68.1M | $-110.7M | ||
| Q1 25 | $45.2M | $-167.8M | ||
| Q4 24 | $124.9M | $-79.5M | ||
| Q3 24 | $37.0M | $-68.6M | ||
| Q2 24 | $27.9M | $-79.0M | ||
| Q1 24 | $18.3M | $-193.9M |
自由现金流率DAVERARE
| Q4 25 | 177.0% | -48.6% | ||
| Q3 25 | 55.2% | -58.0% | ||
| Q2 25 | 51.7% | -66.5% | ||
| Q1 25 | 41.9% | -120.5% | ||
| Q4 24 | 123.8% | -48.3% | ||
| Q3 24 | 40.0% | -49.2% | ||
| Q2 24 | 34.8% | -53.7% | ||
| Q1 24 | 24.9% | -178.2% |
资本支出强度DAVERARE
| Q4 25 | 0.2% | 0.5% | ||
| Q3 25 | 0.0% | 0.8% | ||
| Q2 25 | 0.1% | 1.5% | ||
| Q1 25 | 0.0% | 1.0% | ||
| Q4 24 | 0.3% | 0.1% | ||
| Q3 24 | 0.1% | 1.2% | ||
| Q2 24 | 0.2% | 1.4% | ||
| Q1 24 | 0.0% | 3.0% |
现金转化率DAVERARE
| Q4 25 | 4.40× | — | ||
| Q3 25 | 0.90× | — | ||
| Q2 25 | 7.55× | — | ||
| Q1 25 | 1.57× | — | ||
| Q4 24 | 7.45× | — | ||
| Q3 24 | 79.47× | — | ||
| Q2 24 | 4.41× | — | ||
| Q1 24 | 0.54× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DAVE
| Service Based Revenue | $153.2M | 94% |
| Interchange Revenue Net | $6.4M | 4% |
| Transaction Based Revenue Other Net | $4.1M | 3% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
